NGMCNext Generation Management Corp.
The schedule
- Tue8Sep
- Thu12Nov
- Thu14Jan
- Thu25Mar
- Thu13May
Past
- Sat15Aug
Actual outcome: Bull · $1.03 at outcome
NGMC's stock surged following FDA approval of its flagship therapy, which significantly enhances its market position and revenue potential. The approval was a major milestone, validating the drug's efficacy and safety, and unlocking commercialization opportunities. This event directly drove the extraordinary short-term price move. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +930.0% from 2026-07-31 to 2026-08-18 (~6.9σ vs typical 10d vol). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-18). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +930.0% from 2026-07-31 (~6.9σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-20). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +930.0% from 2026-07-31 (~6.9σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-24).
NGMC's stock surged following FDA approval of its flagship therapy, which significantly enhances its market position and revenue potential. The approval was a major milestone, validating the drug's efficacy and safety, and unlocking commercialization opportunities. This event directly drove the extraordinary short-term price move. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +930.0% from 2026-07-31 to 2026-08-18 (~6.9σ vs typical 10d vol). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-18). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +930.0% from 2026-07-31 (~6.9σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-20). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +930.0% from 2026-07-31 (~6.9σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-24).
- Wed1Jul
Actual outcome: Bull · $0.00 at outcome
NGMC delivered a significant earnings beat with strong revenue growth and optimistic forward guidance, leading to a sharp upward move. The results exceeded analyst expectations, signaling improved operational performance and potential for sustained growth. The positive momentum was further supported by management's confidence in future earnings potential. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +930.0% from 2026-07-02 to 2026-08-18 (~4.0σ vs typical 30d vol). Target date 2026-08-01 reached; move through 2026-08-18 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-08-20: +930.0% from 2026-07-02 (~4.0σ). Target date 2026-08-01 reached; move through 2026-08-20 observed.
NGMC delivered a significant earnings beat with strong revenue growth and optimistic forward guidance, leading to a sharp upward move. The results exceeded analyst expectations, signaling improved operational performance and potential for sustained growth. The positive momentum was further supported by management's confidence in future earnings potential. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +930.0% from 2026-07-02 to 2026-08-18 (~4.0σ vs typical 30d vol). Target date 2026-08-01 reached; move through 2026-08-18 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-08-20: +930.0% from 2026-07-02 (~4.0σ). Target date 2026-08-01 reached; move through 2026-08-20 observed.